Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358
about
Aurora Kinase Inhibitors: Current Status and OutlookThe growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABLEqually Potent Inhibition of c-Src and Abl by Compounds that Recognize Inactive Kinase ConformationsCrystal Structures of ABL-Related Gene (ABL2) in Complex with Imatinib, Tozasertib (VX-680), and a Type I Inhibitor of the Triazole Carbothioamide ClassConformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036Ponatinib is a pan-BCR-ABL kinase inhibitor: MD simulations and SIE studyOptimizing combination therapies with existing and future CML drugsAllosteric interactions between the myristate- and ATP-site of the Abl kinaseAbcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitroCombination of a proteomics approach and reengineering of meso scale network models for prediction of mode-of-action for tyrosine kinase inhibitorsInhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763/AS703569 and PHA-739358 in BCR-ABL transformed cellsTargeting cancer with small molecule kinase inhibitorsHierarchical modeling of activation mechanisms in the ABL and EGFR kinase domains: thermodynamic and mechanistic catalysts of kinase activation by cancer mutations.Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability.Conformational disturbance in Abl kinase upon mutation and deregulation.Computational modeling of allosteric communication reveals organizing principles of mutation-induced signaling in ABL and EGFR kinases.The energy landscape analysis of cancer mutations in protein kinasesSequence and structure signatures of cancer mutation hotspots in protein kinasesMaternal embryonic leucine zipper kinase: key kinase for stem cell phenotype in glioma and other cancers.Cancer driver mutations in protein kinase genesA type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl.The generation of purinome-targeted libraries as a means to diversify ATP-mimetic chemical classes for lead finding.Measurement of small molecule binding kinetics on a protein microarray by plasmonic-based electrochemical impedance imaging.Evaluating the predictivity of virtual screening for ABL kinase inhibitors to hinder drug resistanceKinase dynamics. Using ancient protein kinases to unravel a modern cancer drug's mechanismAnchor-based classification and type-C inhibitors for tyrosine kinases.A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generatAurora kinase inhibitors as anticancer molecules.JAK3 inhibitor VI is a mutant specific inhibitor for epidermal growth factor receptor with the gatekeeper mutation T790M.Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib)Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy.Target validation and biomarker identification in oncology : the example of aurora kinases.Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution.Overcoming resistance in chronic myelogenous leukemia.Biochemical mechanisms of resistance to small-molecule protein kinase inhibitors.Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias.Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agents.Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia.New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia.
P2860
Q26770583-5162D69E-8652-4C1B-B3F6-35609B16830CQ26866312-B5B44765-ECC4-44C8-931E-09C792076F42Q27654059-2A05A912-55E4-4E54-93F1-096FAB3761A1Q27667290-C42E4310-C7DE-449B-9267-F9EAB989B74CQ27667482-7EFEC86D-0101-4A69-B74D-10D3CB70D10EQ27852657-3FFBD612-C73F-461D-B38C-5657185145E5Q28475255-96147875-80F7-4469-9DB1-B41DDC1573A7Q28476718-FE7ACF4B-9796-4D5B-88FA-2E37C2F170D0Q28477903-56DD8D8B-66B5-4335-AE7A-2CB2ABF89CA0Q28484913-09D24516-FC07-4866-8FAE-54E045F706E5Q28545195-5DAF2BC6-9AAE-4FAE-8CC8-A25778ABD806Q29547395-C23E7B4D-3EB4-496C-9774-508E24C05D77Q30157152-F337251B-B0FE-4384-887E-2E1D82A86A5BQ30374663-8A1C8127-60E7-41E7-8EEB-D996776EE6A3Q30485823-63FF8AED-B5B9-484E-8193-7445FF23FB75Q31036423-0297E687-B2E3-463B-8C5A-9422CF8DA9A3Q31038185-4EA86452-8B41-4BB1-85B6-F812409FE8CAQ33510934-ED8131AA-4B0F-4235-8181-CB423F4A887CQ33723151-5236D9C7-5FFD-497D-BF49-7D3EB624D40EQ34002709-6E9F74FB-FD8E-4407-B411-3DF05A16626AQ34052015-CE2F5B8B-9195-4546-94E1-D1D39278C64DQ34164591-FC10EC1A-2593-45FD-8BDD-0A86032A5BB5Q34300380-8A9B7EB3-B12A-431C-BBB6-C05774FD3E09Q34762595-BA3BBC52-0340-47C0-9803-575C28DBCC4CQ35509663-F24F637B-ADAD-494C-A64F-FCC09BF208AFQ35745479-EE9137F7-3118-44A9-A590-8EF01E3868A9Q35800825-BAB8710A-CE44-44E7-8DF0-5CC7228C6D47Q35850203-8E470BD1-9BFB-4D3A-B839-403884C73CDDQ35858399-D80A07D5-4311-4362-8514-E72EC8FC924EQ36373227-D9E87436-C7C4-4C6F-B4A9-58FF7B1A0EDCQ37109225-D40FB1AD-2C5A-47E1-A1D7-6C8111CCE935Q37141995-DC6EBD30-6FD9-4344-B6F3-FF4589365C5EQ37256808-07EC9FF5-7A8B-41D3-A949-EF3C7BB6B639Q37495481-F8356722-8894-44D7-8DBA-83F4A8B31F4EQ37626054-3503F2FD-BB35-49A2-A556-0EBC8D67119AQ37665845-0D559151-34FF-40D2-91EA-6EE30A83F728Q37690579-EBA52CBD-3D41-417A-8172-C553F945864FQ37763106-B460C25A-A7E9-44F0-9654-C1248B25CA00Q37809083-D166C810-DF76-45C3-9C63-BC810FB31761Q37836938-1A274533-1479-4703-BB96-C143EDA3CE1F
P2860
Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Crystal structure of the T315I ...... a kinases inhibitor PHA-739358
@ast
Crystal structure of the T315I ...... a kinases inhibitor PHA-739358
@en
Crystal structure of the T315I ...... a kinases inhibitor PHA-739358
@nl
type
label
Crystal structure of the T315I ...... a kinases inhibitor PHA-739358
@ast
Crystal structure of the T315I ...... a kinases inhibitor PHA-739358
@en
Crystal structure of the T315I ...... a kinases inhibitor PHA-739358
@nl
prefLabel
Crystal structure of the T315I ...... a kinases inhibitor PHA-739358
@ast
Crystal structure of the T315I ...... a kinases inhibitor PHA-739358
@en
Crystal structure of the T315I ...... a kinases inhibitor PHA-739358
@nl
P2093
P1433
P1476
Crystal structure of the T315I ...... a kinases inhibitor PHA-739358
@en
P2093
Antonella Isacchi
Daniele Fancelli
Elena Casale
Jürgen Moll
Luisa Rusconi
Michele Modugno
Pamela Rosettani
Patrizia Carpinelli
Riccardo Colombo
Rosita Lupi
P304
P356
10.1158/0008-5472.CAN-07-1825
P407
P577
2007-09-01T00:00:00Z